ReviewViruses2021
The Advantages and Challenges of Using Endolysins in a Clinical Setting.
Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 247 citations in OpenAlex.
- S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double-blind randomized clinical trial in patients with mild to moderate atopic dermatitis.British journal of clinical pharmacology · 2026Trial
- Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A dual-functional dendrimer-based system integrating recombinant endolysin and cinnamic acid for enhanced endolysin stability and antibacterial activity against Acinetobacter baumannii.World journal of microbiology & biotechnology · 2026Article
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Domain shuffling of endolysin LysKB317 to controlBiotechnology reports (Amsterdam, Netherlands) · 2026Article
- Antibacterial Efficacy of Recombinant Endolysin S.AgEndo1332 in Combination with Antibiotics against Mastitis-Associated S. aureus in a Mouse Mastitis Model.Probiotics and antimicrobial proteins · 2026Article
- In silico analysis, expression, and characterization of LysStp1 endolysin with L-alanyl-D-glutamate carboxypeptidase activity.Virus genes · 2026Article
- EV-LYSG101: Extracellular Vesicles Loaded With Lysin LYSG101 for Potent Anti-Staphylococcal Activity.Journal of extracellular biology · 2026Article
- Genome-mined endolysin LysMD30 in combination with colistin: synergistic antimicrobial and antibiofilm activities againstApplied and environmental microbiology · 2026Article
- The novel prophage lysin Lys1459 exhibits broad-spectrum antibacterial activity via triple-binding domain.Applied and environmental microbiology · 2026Article
- Helicobacter pylori phages: resource landscape, translational challenges, and engineered antibacterial strategies.Archives of microbiology · 2026Review
- First experimentally characterised Proteus phage endolysins have distinct metal cofactor dependencies.Applied microbiology and biotechnology · 2026Article
- Human Gut Phageome Analysis Uncovers Thousands of Highly Modular Endolysins.MicrobiologyOpen · 2026Article
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Bacteriophage BCP01 and Its Endolysin as Tools for Biocontrol and Rapid Detection ofJournal of microbiology and biotechnology · 2026Article
- Antimicrobial Consumption and Resistance Dynamics Across Healthcare Level: Global Evidence and Stewardship Implications.Pathogens (Basel, Switzerland) · 2026Review
- Review
- Article
- Evaluation of the delivery of an anti-Listeria endolysin via CRISPR-Cas9 engineered probiotic Saccharomyces boulardii.Applied microbiology and biotechnology · 2026Article
- Physicochemical and Proteolytic Barriers Limiting Activity of Cpl-1 and Pal Endolysins in Human Circulation.Current issues in molecular biology · 2026Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic-resistant pathogens are increasingly more prevalent and problematic. Traditional antibiotics are no longer a viable option for dealing with these multidrug-resistant microbes and so new approaches are needed. Bacteriophage-derived proteins such as endolysins could offer one effective solution. Endolysins are bacteriophage-encoded peptidoglycan hydrolases that act to lyse bacterial cells by targeting their cell's wall, particularly in Gram-positive bacteria due to their naturally exposed peptidoglycan layer. These lytic enzymes have received much interest from the scientific community in recent years for their specificity, mode of action, potential for engineering, and lack of resistance mechanisms. Over the past decade, a renewed interest in endolysin therapy has led to a number of successful applications. Recombinant endolysins have been shown to be effective against prominent pathogens such as MRSA,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.